Oncology · Clinical trials
Hepatocellular Carcinoma Clinical Trials
Approved therapies, the pivotal-trial endpoints they were judged on, the magnitude of benefit — and the drugs that failed their endpoints, and why.
Indication overview
About hepatocellular carcinoma — and why its trials are hard
Hepatocellular carcinoma (HCC) is the dominant primary liver malignancy, arising most often against a backdrop of cirrhosis from hepatitis B or C, alcohol, or metabolic (MASH) liver disease. Because underlying liver dysfunction constrains therapy, prognosis and treatment are stratified by both tumor burden and hepatic reserve (Child-Pugh, BCLC staging). For over a decade after sorafenib's 2007 approval, systemic options were limited to multikinase inhibitors. The field transformed in 2020 when the atezolizumab plus bevacizumab combination (IMbrave150) became the first regimen to beat sorafenib on overall survival, establishing immunotherapy-based combinations as first-line standard. Dual checkpoint blockade with durvalumab plus tremelimumab (HIMALAYA STRIDE) followed in 2022, offering a bevacizumab-free option for patients with varices or bleeding risk. Lenvatinib provides a first-line non-immunotherapy alternative, while regorafenib and cabozantinib serve later lines. Overall survival for advanced disease has roughly doubled, though durable responses remain a minority and biomarker-driven selection is still immature.
Approved therapies & pivotal evidence
What's been approved — and by how much it moved the endpoint
| Drug (brand) | Approved | Setting | Pivotal trial | Primary endpoint | Magnitude of benefit |
|---|---|---|---|---|---|
| Atezolizumab + bevacizumab (Tecentriq + Avastin) | 2020 | First-line unresectable/metastatic HCC | IMbrave150 (Phase III) | Overall survival and progression-free survival vs sorafenib | OS HR 0.58 (later updated ~0.66); median OS 19.2 vs 13.4 months |
| Durvalumab + tremelimumab (Imjudo + Imfinzi (STRIDE regimen)) | 2022 | First-line unresectable HCC | HIMALAYA (Phase III) | Overall survival vs sorafenib | OS HR ~0.78; median OS 16.4 vs 13.8 months; 3-year OS ~31% vs 20% |
| Lenvatinib (Lenvima) | 2018 | First-line unresectable HCC | REFLECT (Phase III) | Overall survival (non-inferiority) vs sorafenib | Median OS 13.6 vs 12.3 months; non-inferior, with higher ORR and PFS |
| Sorafenib (Nexavar) | 2007 | First-line advanced HCC (historical standard) | SHARP (Phase III) | Overall survival vs placebo | Median OS 10.7 vs 7.9 months; HR 0.69 |
| Regorafenib (Stivarga) | 2017 | Second-line after sorafenib progression | RESORCE (Phase III) | Overall survival vs placebo | Median OS 10.6 vs 7.8 months; HR 0.63 |
| Cabozantinib (Cabometyx) | 2019 | Second-line after prior systemic therapy | CELESTIAL (Phase III) | Overall survival vs placebo | Median OS 10.2 vs 8.0 months; HR 0.76 |
Where trials have failed
Drugs that missed their endpoint — and what contributed
The most instructive lessons in hepatocellular carcinoma development come from programmes that failed the endpoint that mattered.
| Drug / trial | Endpoint outcome | What contributed |
|---|---|---|
| Sorafenib (adjuvant) — STORM (Phase III) | Failed to improve recurrence-free survival after resection or ablation | No RFS benefit vs placebo (median RFS 33.3 vs 33.7 months); toxicity without efficacy in the adjuvant setting |
| Tivantinib — METIV-HCC (Phase III) | Failed second-line; no overall survival benefit | MET-high selection strategy did not translate to OS gain; questions over MET dependency and drug mechanism |
Choosing the right endpoint
Primary endpoints that matter in hepatocellular carcinoma trials
- Overall survival (OS) — The regulatory gold standard in advanced HCC; most pivotal wins (IMbrave150, SHARP, HIMALAYA) were driven by OS.
- Progression-free survival (PFS) — Frequently co-primary or key secondary; must be interpreted alongside underlying liver function decline.
- Objective response rate (ORR) — Supported accelerated pathways; immunotherapy combinations produce durable but minority responses (~30%).
- Time to progression (TTP) — Used in early TKI trials to separate tumor progression from cirrhosis-related deaths.
- Child-Pugh / liver function preservation — A practical safety endpoint; eligibility and dosing hinge on hepatic reserve, limiting most trials to Child-Pugh A.
How iNGENū runs hepatocellular carcinoma trials
Physician-led design, built for FDA submission
Endpoint & biomarker strategy
Board-certified specialists design endpoints and patient selection aligned to current FDA guidance for this indication.
FDA-ready data
Built to ICH-GCP and 21 CFR 312.120, with direct FDA submission — data accepted by the FDA, EMA and MHRA.
Faster, lower-cost delivery
~4-week ethics via the TGA CTN scheme, up to 43.5% R&D rebate, and 80–90% below US CRO cost.
Request a fixed-milestone proposal and a tailored endpoint & feasibility summary for this indication.
Frequently asked questions
Hepatocellular Carcinoma clinical trials — FAQs
What is the current first-line standard for advanced HCC?
Why did it take so long to improve on sorafenib?
Does liver function affect treatment choice?
Ready to discuss your hepatocellular carcinoma trial?
Talk to our physician-led team about an FDA-ready, cost-efficient trial design.
Request a proposal